The importance of MRD in multiple myeloma in guiding treatment decisions & access to therapies

Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the importance of testing for measurable residual disease (MRD) in patients with multiple myeloma. Dr Landgren first comments on the role that MRD may play as a clinical endpoint and how this may speed up drug development in the field, and then explains the possibility of using MRD to guide treatment decisions. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.